|
|
|
|
| LEADER |
04647nmm a2200373 u 4500 |
| 001 |
EB002002844 |
| 003 |
EBX01000000000000001165745 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
211011 ||| eng |
| 020 |
|
|
|a 9783030797317
|
| 100 |
1 |
|
|a Chuang-Stein, Christy
|
| 245 |
0 |
0 |
|a Quantitative Decisions in Drug Development
|h Elektronische Ressource
|c by Christy Chuang-Stein, Simon Kirby
|
| 250 |
|
|
|a 2nd ed. 2021
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2021, 2021
|
| 300 |
|
|
|a XIX, 342 p. 86 illus., 21 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Chapter 1 - Clinical Testing of a New Drug -- Chapter 2 - A Frequentist Decision-making Framework -- Chapter 3 - Characteristics of a Diagnostic Test -- Chapter 4 - The Parallel Between Clinical Trials and Diagnostic Tests -- Chapter 5 - Incorporating Information from Completed Trials in Future Trial Planning -- Chapter 6 - Choosing Metrics Appropriate for Different Stages of Drug Development -- Chapter 7 - Designing Proof-of-Concept Trials with Desired Characteristics -- Chapter 8 - Designing Dose-response Studies with Desired Characteristics -- Chapter 9 - Designing Confirmatory Trials with Desired Characteristics -- Chapter 10 - Designing Phase 4 Trials -- Chapter 11 - Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Chapter 12 - Discounting Prior Results to Account for Selection Bias -- Chapter 13 - Adaptive Designs -- Chapter 14 - Additional Topics
|
| 653 |
|
|
|a Statistical Theory and Methods
|
| 653 |
|
|
|a Methodology of Data Collection and Processing
|
| 653 |
|
|
|a Sampling (Statistics)
|
| 653 |
|
|
|a Statistics
|
| 653 |
|
|
|a Biostatistics
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Biometry
|
| 700 |
1 |
|
|a Kirby, Simon
|e [author]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Springer Series in Pharmaceutical Statistics
|
| 028 |
5 |
0 |
|a 10.1007/978-3-030-79731-7
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-79731-7?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 519.5
|
| 520 |
|
|
|a This book focuses on important decision points and evidence needed for making decisions at these points during the development of a new drug. It takes a holistic approach towards drug development by incorporating explicitly knowledge learned from the earlier part of the development and available historical information into decisions at later stages. In addition, the book shares lessons learned from several select examples published in the literature since the publication of the first edition. The second edition reiterates the need for making evidence-based Go/No Go decisions in drug development discussed in the first edition. It substantially expands several topics that have seen great advances since the publication of the first edition.
|
| 520 |
|
|
|a Using the concept of the positive predictive value in the field of diagnostics, the book leads readers to the assessment of the probability that an investigational product is effective given positive study outcomes. Lastly, the book points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves
|
| 520 |
|
|
|a The most noticeable additions include three adaptive trials conducted in recent years that offer excellent learning opportunities, the use of historical data in the design and analysis of clinical trials, and extending decision criteria tothe cases when the primary endpoint is binary. The examples used to illustrate the additional materials all come from real trials with some post-trial reflections offered by the authors. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. Prior knowledge includes information pertaining to historical controls. To assist decision making, the book discusses appropriate metrics and the formulation of go/no-go decisions for progressing a drug candidate to the next development stage.
|